Ymchwil Iechyd a Gofal Cymru
Health and Care Research Wales

NHS
Health Research Authority

Dr Damien Longson
Greater Manchester Mental Health NHS Foundation Trust
Harrop House, Bury New Road
Prestwich Manchester
M25 3BL

Email: approvals@hra.nhs.uk
HCRW.approvals@wales.nhs.uk

08 July 2021

Dear Dr Longson

HRA and Health and Care Research Wales (HCRW) Approval Letter

Study title:	**A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder**
IRAS project ID:	**294656**
EudraCT number:	**2020-004653-69**
Protocol number:	**BHV4157-303**
REC reference:	**21/NW/0137**
Sponsor	**Biohaven Pharmaceuticals, Inc.**

I am pleased to confirm that **HRA and Health and Care Research Wales (HCRW) Approval** has been given for the above referenced study, on the basis described in the application form, protocol, supporting documentation and any clarifications received. You should not expect to receive anything further relating to this application.

Please now work with participating NHS organisations to confirm capacity and capability, in line with the instructions provided in the "Information to support study set up" section towards the end of this letter.

How should I work with participating NHS/HSC organisations in Northern Ireland and Scotland?

HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland and Scotland.

If you indicated in your IRAS form that you do have participating organisations in either of these devolved administrations, the final document set and the study wide governance report

(including this letter) have been sent to the coordinating centre of each participating nation. The relevant national coordinating function/s will contact you as appropriate.

Please see IRAS Help for information on working with NHS/HSC organisations in Northern Ireland and Scotland.

How should I work with participating non-NHS organisations?
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with your non-NHS organisations to obtain local agreement in accordance with their procedures.

What are my notification responsibilities during the study?

The standard conditions document "*After Ethical Review – guidance for sponsors and investigators*", issued with your REC favourable opinion, gives detailed guidance on reporting expectations for studies, including:

- Registration of research
- Notifying amendments
- Notifying the end of the study

The HRA website also provides guidance on these topics, and is updated in the light of changes in reporting expectations or procedures.

Who should I contact for further information?
Please do not hesitate to contact me for assistance with this application. My contact details are below.

Your IRAS project ID is **294656**. Please quote this on all correspondence.

Yours sincerely,
Margaret Hutchinson

Approvals Specialist

Email: approvals@hra.nhs.uk

Copy to: *Dr. Vlada Injac*

List of Documents

The final document set assessed and approved by HRA and HCRW Approval is listed below.

Document	*Version*	*Date*
Confirmation of Clinical Trial Authorisation from MHRA and relevant correspondence [MHRA Clinical Trial Acceptance]	n/a	18 March 2021
Contract/Study Agreement template [GMMH_Clinical Trial Agreement]	n/a	
Contract/Study Agreement template [SABP_Clinical Trial Agrrement]	n/a	
Contract/Study Agreement template [SWLSTG_Clinical Trial Agreement]	n/a	
Contract/Study Agreement template [MAC_Clinical Trial Agreement]		
Copies of materials calling attention of potential participants to the research [Campaign media text]	version 3.0 (TC)	16 June 2021
Copies of materials calling attention of potential participants to the research [Recruitment material]	n/a	
Copies of materials calling attention of potential participants to the research [GP]	1.0	31 March 2021
Copies of materials calling attention of potential participants to the research [Study Information Sheet]	1.0	31 March 2021
Copies of materials calling attention of potential participants to the research [Telephone Screen Eligibility]	1.0	31 March 2021
Copies of materials calling attention of potential participants to the research [Telephone Dialogue]	1.0	31 March 2021
Costing template (commercial projects) [Costing Template Validation]	n/a	13 April 2021
Covering letter on headed paper [Application lette]	n/a	16 April 2021
Covering letter on headed paper [Application lette]	n/a	17 June 2021
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [UK_Insurance Certificate]	n/a	02 December 2020
GP/consultant information sheets or letters [GP letter]	version 1.1 (TC)	08 June 2021
Investigator's brochure / IMP Dossier [TSE/BSE Catalent 140]		01 December 2020
Investigator's brochure / IMP Dossier [TSE/BSE Catalent Placebo 140]		01 December 2020
Investigator's brochure / IMP Dossier [IB]	6.0	24 August 2020
Investigator's brochure / IMP Dossier [Outline of Active trials]	n/a	22 December 2020
Investigator's brochure / IMP Dossier [IMPD]	01	14 December 2020
Investigator's brochure / IMP Dossier [Stability Appendix]	n/a	
Investigator's brochure / IMP Dossier [Stability Appendix]	n/a	
Investigator's brochure / IMP Dossier [IMPD DS Neuland]	01	14 December 2020
Investigator's brochure / IMP Dossier [IMPD Placebo]	01	14 December 2020
Investigator's brochure / IMP Dossier [TSE/BSE DS]		30 August 2020
Investigator's brochure / IMP Dossier [TSE/BSE]		28 March 2020
Investigator's brochure / IMP Dossier [TSE/BSE Catalent]		01 December 2020
Investigator's brochure / IMP Dossier [TSE/BSE Catalent Placebo]		01 December 2020
IRAS Application Form [IRAS_Form_19042021]		19 April 2021
IRAS Checklist XML [Checklist_19042021]		19 April 2021

Letters of invitation to participant [Invitation letter]	1.0	01 April 2021
Other [GCP Certificate_PI_A_Asher]	n/a	26 May 2020
Other [GCP Certificate_PI_P_Westhead]	n/a	21 July 2020
Other [GCP of NCI]	N/A	13 February 2020
Other [List of CAs]	n/a	15 April 2021
Other [Covid-19 Vaccine_Note to File]	n/a	15 April 2021
Other [GCP Certificate_PI_V_Lynch]	n/a	01 September 2020
Other [Confirmation of EudraCT Number]	n/a	25 September 2020
Other [MAC_Insurance Certificate]	n/a	11 June 2020
Other [UK_ACC_Conf Statement]	n/a	23 December 2020
Other [UK_LoA_ACC to Local_Applicant]	n/a	04 February 2021
Other [UK_LoA to ACC]	n/a	18 December 2020
Other [Recruitment Statement]	n/a	24 November 2020
Other [CV_PI_A_Babajide]	n/a	02 March 2021
Other [CV_PI_I_Pampaloni]	n/a	16 March 2021
Other [CV_PI_L_Vivarelli]	n/a	28 September 2020
Other [CV_PI_A_Asher]	n/a	04 January 2021
Other [CV_PI_P_Westhead]	n/a	03 September 2020
Other [CV_PI_V_Lynch]	n/a	20 January 2021
Other [GCP Certificate_A_Babajide]	n/a	21 January 2021
Other [GCP Certificate_PI_I_Pampaloni]	n/a	14 April 2021
Other [GCP Certificate_PI_L_Vivarelli]	n/a	17 January 2020
Other [Confirmation of addtional NHS Site]		21 June 2021
Participant consent form [ICF main]	version 1.1 (TC)	08 June 2021
Participant consent form [ICF pregnancy]	version 1.1 (TC)	08 June 2021
Participant consent form [ICF genetic]	1.0	01 April 2021
Participant information sheet (PIS) [PIS genetic]	1.0	01 April 2021
Participant information sheet (PIS) [PIS main]	version 1.1 (TC)	08 June 2021
Participant information sheet (PIS) [PIS pregnancy]	version 1.1 (TC)	08 June 2021
Research protocol or project proposal [Protocol]	01.2	15 March 2021
Sample diary card/patient card [Participant ID Card]	1.0	01 April 2021
Summary CV for Chief Investigator (CI) [NCI CV]	NA	03 February 2021
Summary, synopsis or diagram (flowchart) of protocol in non technical language [Protocol Summary]	1.0	05 April 2021
Validated questionnaire [Y-BOCS]		
Validated questionnaire [MGH-TRQ-OCD]		
Validated questionnaire [BABS]		
Validated questionnaire [BAI]		
Validated questionnaire [MINI Standard]		
Validated questionnaire [MINI BDP]		

Validated questionnaire [CGI-I]		
Validated questionnaire [CGI-S]		
Validated questionnaire [C-SSRS Screening]		
Validated questionnaire [C-SSRS Since Last Visit]		
Validated questionnaire [RCRS]		
Validated questionnaire [QIDS-SR16]		
Validated questionnaire [SDS]		
Validated questionnaire [DOCS]		

IRAS project ID	294656

Information to support study set up

The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS organisations in England and Wales. This is intended to be an accurate reflection of the study at the time of issue of this letter.

Types of participating NHS organisation	Expectations related to confirmation of capacity and capability	Agreement to be used	Funding arrangements	Oversight expectations	HR Good Practice Resource Pack expectations
All sites will perform the same research activities therefore there is only one site type.	Research activities should not commence at participating NHS organisations in England or Wales prior to their formal confirmation of capacity and capability to deliver the study.	The sponsor has supplied the appropriate current unmodified model agreement, and intends to use this with participating NHS organisations. HRA and HCRW Approval is conditional on this unmodified agreement being used with participating NHS organisations	No external funding has been applied for.	A Principal Investigator should be appointed at study sites	No Honorary Research Contracts, Letters of Access or pre-engagement checks are expected for local staff employed by the participating NHS organisations. Where arrangements are not already in place, research staff not employed by the NHS host organisation undertaking any of the research activities listed in the research application would be expected to obtain an honorary research contract from one NHS organisation (if university employed), followed by Letters of Access for subsequent organisations. This would be on the basis of a Research Passport (if university employed) or an NHS to NHS confirmation of pre-engagement

					checks letter (if NHS employed). These should confirm enhanced DBS checks, including appropriate barred list checks, and occupational health clearance.

Other information to aid study set-up and delivery

This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up.
The applicant has indicated that they intend to apply for inclusion on the NIHR CRN Portfolio.